Skip to main content
. 2019 May 10;8(5):442. doi: 10.3390/cells8050442

Figure 2.

Figure 2

Lung cancer The Cancer Genome Atlas (TCGA) data for genomic alterations on the RKIP encoding gene (PEBP1). (a) Number of cases depicting RKIP genomic alterations in the different histological types (from an analysis of 17 different studies containing 4028 samples). (b) Scheme showing distribution of PEBP1 mutations in the entire RKIP protein. (c) Kaplan–Meier analysis of NSCLC patient’s overall survival (OS) in months distributed by the presence (red line: 6.18 months of median OS, from 6 patients) or absence (blue line: 43.91 months of median OS, from 948 patients) of RKIP gene alterations (p < 0.05). (d) RNA Seq V2 data, showing the mean of RKIP mRNA expression levels in AC (566 patients) and SCC (487 patients). (e) Percentage of cases depicting mRNA up and downregulation in the different NSCLC histological types (refers to a total of 1094 cases). (f) Kaplan–Meier analysis of NSCLC patient’s progression-free survival in months, distributed by the presence (red line, 31 cases for AC and 27 SCC) or absence (blue line, 475 cases for AC and 348 SCC) of RKIP mRNA alterations. All data is available at www.cbioportal.org. SCLC: Small Cell Lung Carcinoma; NSCLC: Non-Small Cell Lung Carcinoma; AC: Adenocarcinoma; SCC: Squamous cell Carcinoma.